Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Energy & Commerce Committee restructuring

Executive Summary

House Energy & Commerce Committee will focus on oversight functions under new Chairman Joe Barton (R-Texas). Medicaid and Medicare costs will be one focus. Rep. Billy Tauzin (R-La.) resigned as chair Feb. 18 (1"The Pink Sheet" March 1, 2004, p. 23). Staffing changes are also underway; Chief Health Counsel Patrick Morrisey is leaving Capitol Hill to join law firm Sidley Austin Brown & Wood...

You may also be interested in...

PhRMA CEO Search On Hold; Tauzin Will Wait On Decision

Rep. Billy Tauzin (R-La.) has suspended discussions with the Pharmaceutical Research & Manufacturers of America to become the trade association's CEO, his office said Feb. 26

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?

ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN

Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts